GlassScriptPhysician profile
William Alexander Wade
NPI 1003029075
$6,543.34
in general payments reported to CMS, 2019-2025
22 companies · $19.36 in 2025
The $19.36 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $484 · 2021: $562 · 2022: $352 · 2023: $544 · 2024: $4,045 · 2025: $19.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,647 · Travel and Lodging: $1,205 · Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,646.98 |
| Travel and Lodging | $1,205.21 |
| Food and Beverage | $757.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,722.20 | 2024 | |
| Glaxosmithkline, LLC. | $865.09 | 2019-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $732.44 | 2019-2024 | |
| Genentech USA, INC. | $254.81 | 2019-2024 | Xolair |
| Genzyme Corporation | $193.91 | 2021-2024 | |
| Actelion Pharmaceuticals US, INC. | $146.98 | 2023-2024 | Opsumit, Uptravi |
| Pfizer INC. | $104.80 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $62.39 | 2020-2021 | |
| Insmed, INC. | $51.31 | 2022-2024 | Arikayce |
| Advanced Respiratory, INC | $51.08 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $46.78 | 2021-2022 | |
| Grifols USA, LLC | $46.24 | 2020-2024 | Prolastin-C Liquid |
| Csl Behring | $38.69 | 2020 | |
| Jazz Pharmaceuticals INC. | $38.29 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $37.05 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $32.68 | 2019-2020 | |
| Electromed, INC. | $28.25 | 2019 | |
| La Jolla Pharmaceutical Company | $25.90 | 2020-2021 | |
| Apria Healthcare LLC | $22.46 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.90 | 2022 | |
| Abbvie INC. | $13.41 | 2023 | Avycaz |
| Allergan, INC. | $12.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.